Liming X. Wu

No. 261 Huansha Road
Hangzhou, 310006, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 128 publications

Stapokibart reduces blood eosinophil counts in patients with moderate-to-severe atopic dermatitis: a post-hoc analysis from phase II and phase III clinical trials.

Stapokibart reduces blood eosinophil counts in patients with moderate-to-severe atopic dermatitis: a post-hoc analysis from phase II and phase III clinical trials.

Journal: The Journal of dermatological treatment

Published: July 15, 2026

Safety and effectiveness of omalizumab for chronic spontaneous urticaria inadequately controlled with H1 antihistamines in Chinese adolescents: a real-world, prospective, multicenter study.

Safety and effectiveness of omalizumab for chronic spontaneous urticaria inadequately controlled with H1 antihistamines in Chinese adolescents: a real-world, prospective, multicenter study.

Journal: The Journal of dermatological treatment

Published: July 13, 2026

Stapokibart provides significant improvements in signs and symptoms of atopic dermatitis irrespective of prior systemic treatment: a post-hoc analysis of a phase 3 trial.

Stapokibart provides significant improvements in signs and symptoms of atopic dermatitis irrespective of prior systemic treatment: a post-hoc analysis of a phase 3 trial.

Journal: The Journal of dermatological treatment

Published: July 06, 2026

Efficacy and Safety of Recibokibart, an Interleukin-36 Receptor Antibody, in Generalized Pustular Psoriasis: A Phase 2 Randomized Trial.

Efficacy and Safety of Recibokibart, an Interleukin-36 Receptor Antibody, in Generalized Pustular Psoriasis: A Phase 2 Randomized Trial.

Journal: The British journal of dermatology

Published: May 21, 2026

Substrate-mediated spatial cooperation in Bacillus-Saccharomyces consortia enhance starch hydrolysis and flavor formation during solid-state fermentation.

Substrate-mediated spatial cooperation in Bacillus-Saccharomyces consortia enhance starch hydrolysis and flavor formation during solid-state fermentation.

Journal: Bioresource technology

Published: May 15, 2026

Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial.

Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial.

Journal: Dermatology and therapy

Published: April 10, 2026

Magnetometry for Agriculture and Animal Systems: From Classical Sensors to Quantum-Enabled Biosensing.

Magnetometry for Agriculture and Animal Systems: From Classical Sensors to Quantum-Enabled Biosensing.

Journal: Biosensors

Published: March 14, 2026

SSGJ-608 in moderate-to-severe plaque psoriasis: a multicenter, randomized, open-label, phase 3 study.

SSGJ-608 in moderate-to-severe plaque psoriasis: a multicenter, randomized, open-label, phase 3 study.

Journal: Frontiers in immunology

Published: February 13, 2026

Discovery of High-Performance Ni0.62Fe0.23Ce0.15O Electrocatalyst for Oxygen Evolution Reaction via Active Machine Learning.

Discovery of High-Performance Ni0.62Fe0.23Ce0.15O Electrocatalyst for Oxygen Evolution Reaction via Active Machine Learning.

Journal: ACS nano

Published: January 30, 2026

Therapeutic Efficacy and Safety of Recombinant Botulinum Toxin Type A for Moderate to Severe Glabellar Lines: A Randomized, Controlled, Double-blind, Phase III Trial in Chinese Adults.

Therapeutic Efficacy and Safety of Recombinant Botulinum Toxin Type A for Moderate to Severe Glabellar Lines: A Randomized, Controlled, Double-blind, Phase III Trial in Chinese Adults.

Journal: Aesthetic surgery journal

Published: January 29, 2026

Abrocitinib Treatment in Diffuse Alopecia Areata: A Case Report and a Literature Review.

Abrocitinib Treatment in Diffuse Alopecia Areata: A Case Report and a Literature Review.

Journal: Clinical case reports

Published: January 19, 2026

HS-20137 for Chinese Moderate-to-Severe Psoriasis: A Randomized, Double-Blinded, Phase 2 Study.

HS-20137 for Chinese Moderate-to-Severe Psoriasis: A Randomized, Double-Blinded, Phase 2 Study.

Journal: Dermatology and therapy

Published: January 14, 2026

Showing 1-12 of 128

Last Updated: 09/26/2026